Streetbeat News

Price Targets

CTGO

Cormark Securities has initiated coverage on Contango Ore (AMEX:CTGO) with a Buy rating and set a price target of $27.5.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 7:30 pm

FDX

UBS analyst Thomas Wadewitz maintains a Buy rating on FedEx (NYSE:FDX) and raises the price target from $323 to $340.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 7:23 pm

KIM

Kimco Realty's stock trades lower following a downgrade by Citigroup from Buy to Neutral, with a reduced price target from $26 to $20.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 7:16 pm

NVDA

NVIDIA's stock price increased following UBS's decision to maintain a Buy rating and raise its price target from $800 to $1,100.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 7:04 pm

ABBV

In the last three months, 7 analysts have updated their ratings on AbbVie (NYSE:ABBV), showing a positive trend with 2 bullish and 5 somewhat bullish ratings. The average 12-month price target for ABBV has been raised to $188.29, indicating a 4.44% increase from the previous target. Analysts from firms like Guggenheim, Raymond James, and Barclays have raised their price targets, reflecting optimism about AbbVie's future performance despite recent challenges in revenue growth and profitability metrics.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 7:01 pm

ABSI

Six analysts have recently assessed Absci (NASDAQ:ABSI), showing a mix of bullish and somewhat bullish ratings with an average 12-month price target of $8.17, a significant increase from the previous $4.00. Absci, an AI-powered synthetic biology company, has seen a revenue decline of -68.59% over the past 3 months, with a net margin of -2956.18%, ROE of -10.68%, and ROA of -8.97%. Despite the financial challenges, the company's market position remains strong with a low debt-to-equity ratio of 0.09.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 7:01 pm

FDS

FactSet Research Systems (NYSE:FDS) received mixed analyst ratings with 3 indifferent and 1 bearish over the past three months. The average 12-month price target is $453.0, reflecting a 5.72% increase from the previous $428.50. Analyst actions include maintaining, raising, and lowering ratings with price targets adjusted accordingly. FactSet's financial performance shows positive revenue growth, high net margin, ROE, and ROA, but faces challenges in market capitalization and debt management.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 7:00 pm

DRI

Darden Restaurants Inc (NYSE:DRI) reported Q3 FY24 sales of $2.975 billion, missing estimates, with a 6.8% Y/Y growth. Adjusted EPS was $2.62, in line with expectations. FY24 sales forecast was revised to $11.4 billion from $11.5 billion, with same-restaurant sales growth expectations lowered to 1.5%-2%. Following the earnings announcement, analysts from Citigroup, JP Morgan, Morgan Stanley, Wedbush, and Oppenheimer adjusted their price targets on DRI, all maintaining positive ratings but lowering their price targets. DRI shares rose 0.9% to $164.75.

Portfolio Pulse from Avi Kapoor

March 22, 2024 | 6:58 pm

XFOR

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterated a Buy rating on X4 Pharmaceuticals (NASDAQ:XFOR) and maintained a $3 price target.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 6:54 pm

ABSI

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterated a Buy rating on Absci (NASDAQ:ABSI) and maintained a $7 price target.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 6:52 pm